Morgan Stanley raised the firm’s price target on Intra-Cellular to $95 from $92 and keeps an Overweight rating on the shares. The firm’s estimates are in line with consensus on Caplyta revenues and ahead of the sNDA filing for adjunct MDD, it would listen for updates on the sales force expansion, including the addition of the 150 sales representatives in Q3 and second expansion next year, the analyst tells investors in a preview note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular announces presentations at 2024 ECNP Congress
- Broadcom AI results fail to enthuse the Street: Morning Buzz
- Piper upgrades Intra-Cellular on potential in major depressive disorder
- Intra-Cellular upgraded to Overweight from Neutral at Piper Sandler
- Intra-Cellular price target raised to $81 from $79 at JPMorgan